OTOrien L. Tulp

Orien L. Tulp

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Orien L. Tulp has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The Effects of Aging, Epigenetic Expression, and Obese Phenotype on Parameters of Glycemic Status, Glucose Oxidation, Insulin Resistance and Adiposity in the Congenic LA/Ntul//-cp Rat

    by Orien L Tulp

    Pathophysiologic manifestations of systemic Insulin resistance (IR) in association with obesity and overweight conditions are a common observation in man and animals. The purpose of the current investigation was to determine the characteristics of adiposity, IR, and insulin-stimulated glucose oxidation (ISGOX) in diaphragm muscle in normally reared and fed aging female congenic, lean and obese LA/Ntul//-cp rats from 4 to 24 months of age. Insulin resistance (IR) in the diaphragm muscle is a condition where the muscle under fixed glucose concentrations may become less responsive to insulin, thereby impairing glucose uptake and potentially contributing to progressive diaphragmatic weakness and respiratory dysfunction. Thus, IR may become a contributor to insulin resistance in muscle and adipose tissue depots particularly in conditions like obesity and obesity linked comorbidities including type 2 diabetes (T2DM/NIDDM). While peripheral skeletal musculature groups often represent a primary locale of IR in man and animals, the ongoing physiologic contractile activity of the diaphragm muscle may escape much of the early impact of IR since it remains a more physiologically active muscle group than skeletal muscle groups throughout the lifespan in man and animals, and thus may confer a measure of metabolic protection from more extensive features of IR. Groups of lean and obese female littermate LA/Ntul//-cp rats, a rodent model where epigenetic obesity occurs independently of NIDDM were studied at 4, 14, and 24 months of age. Parameters of adiposity, IR and ISGOX in diaphragm muscle were determined in the presence or absence of insulin (100 µU/ml; medium glucose 10 mM). Relative adiposity was computed by the addition of the sum of dorsal and retroperitoneal adipose tissue depots as a proportion of final body weight. Body weight of lean animals was similar at all ages studied, while body weight of obese rats increased further at each successive age studied. Fasting plasma glucose concentrations were similar in both phenotypes at all ages studied, but plasma insulin concentrations and the insulin:glucose ratios, established biomarkers of IR, were markedly elevated in the obese phenotype, with only modest age-related improvement. Measures of basal and ISGOX in diaphragm were consistent with age related decreases in baseline and insulin-stimulated glucose oxidation in the lean phenotype. In contrast, baseline and ISGOX in the obese phenotype were consistent with IR. These results suggest that the capacity for insulin-stimulated glucose oxidation and energy metabolism decreased by advances in aging in this muscle group in concert with progressive increases in adiposity with aging.

  • Open Access

    Impact of an Intermittent Complex Carbohydrate Regimen on Insulin Resistance and Adiposity in Congenic, Lean and Obese LA/Ntul//-cp Rats

    by Orien L. Tulp, Cecelia C. Carlin

    Chronic nutritionally induced increases in insulin resistance contribute to the progression of cardiometabolic disorders in man and animals. To determine the impact on adiposity, complex carbohydrate in the form of Polycose® was fed ad libitum intermittently to congenic lean and obese LA/Ntul//-cp rats as a 25% (w/v) dietary carbohydrate supplement in drinking water in addition to stock Purina chow and house water from 3 until 12 months of age. Final Body weights of chow-fed obese rats were 2.2-fold greater than their lean littermates, and Polycose® supplemental feeding was associated with 17% and 19% increases in final body weight in both lean and obese phenotypes respectively. The combined mass of the primary white adipose tissue (WAT) depots was 8.6-fold greater in the obese than in their similarly fed lean littermates, and the Polycose® regimen was associated with a 2.7-fold increase in the dorsal WAT depots and a 1.5-fold increase in the retroperitoneal and inguinal WAT depots in the obese phenotype. The Polycose®-associated increases in adiposity were consistent with the result of adipocyte hypertrophy and hyperplasia in both phenotypes. Interscapular brown adipose tissue (IBAT) mass of obese >> lean, and Polycose® was associated with a 1.9-fold increase in IBAT mass in the lean phenotype but was without further increases in the obese phenotype. Baseline- and insulin stimulated in vitro glucose oxidation in diaphragm occurred normally in the lean phenotype but was impaired by over 50% in the obese phenotype, consistent with a decrease in insulin sensitivity and impaired oxidative metabolism in the obese animals. Measures of these observations confirm the marked adiposity of the obese phenotype of this strain, and suggest that long -term complex-CHO supplementations may contribute to an enhancement in the capacity for energy expenditure via non-shivering thermogenesis in IBAT in the lean phenotype, thereby partially buffering the against a propensity for overly excessive fat accretion, but that the capacity for IBAT-mediated NST and mechanisms of lipid accretion and energetic efficiency in the obese phenotype may be impaired thereby further enhancing their propensity for fat accretion and the development of obesity via a combination of depot-specific lipid accretion via hyperplasia and hypertrophy of adipocytes in both abdominal and subcutaneous depots.

  • Open Access

    Effect of Acute Cold Exposure on Differential Expression of Tissue D-I and D-II Iodothyroinine Deiodinase [T4-5’-Deiodinase] Activity in Congenic Lean and Obese LA/Ntul//-cp Rats: Iodothyroinine Deiodinase Activity in Obese Rats

    by Orien L Tulp, Frantz Sainvil, Aftab Awan, Syed A. A Rizvi

    Thyroid hormones are known to play a critical role in metabolic adaptation to chronic changes in diet and environment. The prohormone tetraiodothyronine (T4) is converted to the active form, triiodothyronine (T3) in peripheral tissues via actions of outer ring deiodination by D-I or D-II isoforms of T4-5’ deiodinase activity. In contrast, T4 may also become inactivated during periods of caloric depravation via an inner tyrosyl ring D-III deiodinase to form an inactive hormone, 3’5’3 triiodothyronine, or ‘reverse T3’ (rT3). Measures of D-I and D-II were determined in selected tissues obtained from congenic adolescent lean and obese female LA/Ntul//-cp rats when 16 weeks of age following laboratory temperature exposure of 22°C or 14 hours acute cold exposure at 4°C. Circulating T4 concentrations were similar in lean and obese rats and serum T3 but not T4 concentrations increased dramatically in both phenotypes following the cold exposure, consistent with phenotype- and maximal tissue-linked changes in outer ring T4-5’-deiodinase activity / mg tissue protein and per depot. In Gastrocnemius muscle, only D-II was detected, and gastrocnemius D-II activity of obese increased modestly following cold exposure. In Liver, Kidney, and IBAT and in cold-induced temperature exposure linked increases in IBAT deiodinase activity / mg tissue protein in this strain, but when D-I and D-II deiodinase activity were computed / tissue mass however further analysis indicated that D-I was the predominating adaptive deiodinase in liver, kidney, and gastrocnemius muscle, while in IBAT D-II > D-I activity / IBAT depot and was greater in obese than lean rats. Cold exposure was associated with modest increases in net deiodinase activity only in kidney. Thus, the cold induced increases in circulating T3 in lean and obese rats following cold exposure are likely attributed at least in part to modest increases in IBAT outer ring T4-5’ D-II and renal D-I deiodinase activity, in addition to likely attaining maximal rates of conversion in other peripheral tissues in addition to possible combination with decreases in hormone clearance rates and enhanced receptor occupancy during cold induced stress, and where they contribute to protective measures during dietary or environmental stress.


  • Open Access

    Luminal α-glucosidase inhibition improves insulin sensitivity and modulates glycemic and lipid profiles in obese rats with type 2 diabetes mellitus

    by Orien L. Tulp, Syed A. A. Rizvi

    Atherogenic plasma lipid and glycemic profiles are commonly observed in obesity and adult-onset type 2 diabetes mellitus (T2DM) and may improve following therapeutic intervention. The effects of the luminal α-glucosidase inhibitor miglitol (MIG) on carbohydrate digestion and plasma lipid profiles were evaluated in adult male obese spontaneously hypertensive and diabetes-prone/Ntul//-cp rats, a genetic model that develops early-onset obesity and T2DM independently of diet. Rats were fed either a nutritionally complete diet (formulated by the United States Department of Agriculture) containing 54% sucrose as the carbohydrate component (control) or the same diet supplemented with MIG at 150 mg/kg of diet admixture ad libitum for <8 weeks. MIG treatment resulted in a ~15% decrease in energy intake (p<0.05), net weight gain (p<0.05), and a 14% decrease in adiposity (p<0.05), along with significant decreases in fasting glucose, insulin, and glycated hemoglobin (p<0.05). In addition, MIG reduced the glucose area under the curve by 20% (p<0.05), triglycerides by 15% (p<0.05), and the total cholesterol, α-lipoprotein (low-density lipoprotein), and β-lipoprotein (high-density lipoprotein) fractions by 20% (p<0.05, all comparisons). MIG regimen also led to decreases in liver glucokinase, malic enzyme, and glucose-6-phosphate dehydrogenase (p<0.05). In conclusion, these results suggest that therapeutic α-glucosidase inhibition through MIG improves multiple insulin-related atherogenic parameters and may serve as a useful adjunct in the long-term clinical management of plasma lipid and glycemic profiles in the glucose-intolerant states of obesity and T2DM.

  • Open Access

    Impact of Brown Adipose Tissue Reduction and Overfeeding on Adiposity and Depotspecific Adipose Tissue Cellularity: Brown Fat Reduction and Adipose Tissue Cellularity

    by Orien L Tulp

    Brown adipose tissue contributes to adaptive changes in metabolic energy expenditure in response to alterations in diet and environmental conditions, thereby assisting an animal to maintain thermoregulation and energy balance in various mammalian species including man and animals. Cafeteria overfeeding of normally lean rats during early postweaning growth typically results in significant hyperplasia and in an increased capacity non-shivering thermogenesis and energy expenditure in brown adipose tissue (BAT). The Interscapular BAT depot is readily surgically accessible and normally represents approximately one third of the total BAT mass in lean Sprague Dawley (SD) rats. The effects of experimental overnutrition via offering a Cafeteria feeding regimen (Café) combined with surgical reduction of the IBAT mass of adipose tissue cellularity and regional fat deposition was determined in lean SD rats during 8 weeks of postweaning growth and development to adulthood. Groups (n= 8 rats/group) of male, SD rats were fed a Purina Chow diet or the Chow diet plus the Café regimen for 52 days from weaning. An additional group of the Chow+Café regimen were subjected to surgical removal of their IBAT at 4 weeks of age and continued on the Chow+Café thereafter (Café-IBAT). At 80 days of age, measures of adiposity including anthropometrics and the mass and adipocyte cellularity in principle abdominal and subcutaneous fat depots were determined. Body weight (BW) and mid-abdominal girth were ~20% greater in Café and Café-IBAT, while linear growth was similar in all groups. The mass of all fat depots was greater in Café fed animals (p= Control in all depots, with further increases in the Inguinal SC depot. Thus, these results are consistent with regional differences in the effects of Café feeding on postweaning adipose tissue hyperplasia, hypertrophy and depot mass and which underwent additional depot-specific differentiation in Café-IBAT. In conclusion, Café resulted in adipocyte hypertrophy in all depots studied, but the partial reduction of BAT mass in Cafe-IBAT rats resulted in only modest additional impact on overall adiposity during overfeeding, with the greatest impact in the ING SC depot, and thereby consistent with potential thermogenic compensation in other BAT depots to partially minimize the overall impact of the Café overfeeding regimen on developing adiposity in this strain.

  • Open Access

    Effect of Aging and Obesity on Parameters of Insulin, T4/T3 Ratios, Metabolic Rates, Sirtuins and Longevity in Congenic LA/Ntul//-cp (Corpulent) Rats

    by Orien Tulp

    Changes in thyroidal activity occur in aging, where they typically exhibit a U-shaped curve for plasma TSH concentrations, with variable responses in other parameters of thyroidal function and peripheral physiological actions and their pathophysiologic sequelae. The LA/Ntul//-cp rat strain, developed from a cross between a Koletsky Rat and an NIH longevity-prone LA/N strain of unknown origin exhibits one of the longest life spans of the various rodent strains that express a trait for early onset obesity in association with impairments in sympathetic and thyroidal components of non-shivering thermogenesis, insulin resistance and energy metabolism. To determine the effects of aging and obesity from adolescence through much of the projected lifespan of the obese phenotype, groups of congenic lean and obese female LA/Ntul//-cp rats were studied from 4 until 24 months of age. Measures of Resting Metabolic rates (RMR), fasting plasma insulin and glucose, T3, T4, plasma half-life of T4, and computation of T4/T3 ratios were determined as an indication of the capacity for deiodination of T4 to T3 in peripheral tissues and its cumulative effects on RMR. Body weight of obese >>> lean at all ages studied. Plasma Insulin was significantly elevated in the obese phenotype, and decreased with advancing age, while plasma glucose remained within the normal fasting range in all rats of both phenotypes. RMR of lean > obese at all ages studied and decreased with advancing age in both phenotypes. Liver T4-5’ deiodinase activity of lean > obese at all ages studied. Plasma T4/T3 ratios decreased with aging in both phenotypes, with the greatest decrease in the obese phenotype. The T1/2 of 131I-T4 was over 40 % longer in the obese phenotype littermates at 4 months of age (p=< 0.01).These results suggest that conversion of T4 to T3 in peripheral tissues in association with attenuation of hyperinsulinemia contributes to decreases in RMR with aging and is further decreased in the obese phenotype, thereby decreasing the quantifiable availability of tissue T3 mass for thyroidal actions at the genomic level, including decreases in harmful reactive oxygen species (ROS) and other entities as products of intermediary metabolism. Thus, the progressive decreases in plasma insulin and deiodination-mediated activation of T4 may represent a longevity attribute via decreases in resting metabolic rates, and in an associated attenuation of free radical generation and other metabolic factors of aging and longevity in this strain.

  • Open Access

    Incretin mimetics for the management of diabetes and associated comorbidities: An overview

    by Faryal Haider, Syed M. Imam, Orien L. Tulp, Syed A. A. Rizvi

    Type 2 diabetes mellitus is commonly associated with various comorbidities that aggravate the disease’s overall impact on health. The most prevalent comorbidities of diabetes include obesity, dyslipidemia, hypertension, cardiovascular conditions, and kidney diseases. Incretin mimetics, also known as glucagon-like peptide-1 receptor agonists, mimic incretin hormones to stimulate insulin release in response to food intake. These medications help lower blood glucose by increasing insulin production, reducing glucagon secretion, slowing stomach emptying, and promoting satiety. A key advantage of incretin mimetics is their ability to reduce blood glucose levels without causing hypoglycemia, making them a safer option for many patients. They also promote weight loss, which is particularly beneficial for patients with both obesity and diabetes. Incretin mimetics are typically administered once or twice daily and are often used in combination with other treatments such as metformin or insulin. Evidence suggests that these drugs may reduce the risk of heart attack and stroke, an important consideration given the heightened cardiovascular risk in patients with diabetes. Additionally, incretin mimetics may help preserve pancreatic beta-cell function, potentially slowing the progression of diabetes. However, these drugs are costly and may be unaffordable for low-income individuals. Commonly reported side effects include nausea, vomiting, and diarrhea, which tend to decrease over time. While there have been reports of pancreatitis, current research indicates that incretin mimetics do not increase the risk of pancreatic cancer. Educating patients on proper use and potential side effects is crucial to ensure safe and effective treatment with incretin mimetics.

  • Open Access

    Luminal Inhibition of α-Glucosidase Activity Improves Insulinogenic Actions on Glycemic and Lipid Parameters in Obese T2DM Rats

    by Orien Tulp, Syed Rizvi

    Inhibitors of luminal α-glucosidase activity are well established agents to improve glycemic parameters in glucose intolerant states, but their secondary insulinogenic effects on plasma lipid profiles are less well established. Atherogenic elevations in plasma lipid profiles are a common observation in overweight, obese, hyperinsulinemic, and adult-onset diabetes (T2DM). The effects of luminal inhibition of starch digestion on parameters of weight gain and plasma lipid profiles were determined in groups of adult male obese T2DM SHR/Ntul//-cp rats. Animals were fed a USDA-formulated, nutritionally complete diet containing 54% sucrose as the carbohydrate component (Control) or the same diet containing a pharmacologic α-glucosidase inhibitor (1,5 dideoxy-1,5-[(2-hydroxyethyl) imino]-D glucitol; generic miglitol), 150 mg/kg diet as an admixture, ad libitum for up to 8 weeks. Miglitol resulted in modest decreases in food intake, net weight gain, adiposity and while the net efficiency of weight gain was similar in both groups. At the end of the study bloods were collected for determination of plasma glucose, Insulin, triglycerides, cholesterol, low-density lipoprotein (LDL) and high-density lipoprotein (HDL) fractions. The miglitol-associated luminal inhibition of α-glucosidase activity resulted in 20% reduction in glucose area under the curve (AUC) and glycosylated hemoglobin, 15% reduction in triglycerides, 20% reduction in total cholesterol, and in both α- (LDL) and β-lipoprotein (HDL) fractions, a 14% decrease in net fat pad mass, and a 10% decrease in net weight gain at the end of the study. These results indicate that simple inhibition of luminal α-glucosidase activity via miglitol may be a useful adjunct in the long-term clinical management of hypercholesterolemia and hypertriglyceridemia in states of obesity, T2DM and other glucose intolerant states, in addition to therapeutic applications in enhancing and improving glycemic control in man and animals.


  • Open Access

    A Brief Review of Incretin Mimetics Intended for the Management of Diabetes and Associated Comorbidities

    by Faryal Haider, Syed Imam, Orien Tulp, Syed Rizvi

    Incretin mimetics, also known as glucagon-like peptide-1 (GLP-1) receptor agonists, are a class of medications used to treat type 2 diabetes by mimicking the actions of incretin hormones in the body. These hormones are responsible for promoting insulin release from the pancreas in response to nutrient intake, as well as decreasing glucagon secretion, slowing gastric emptying, and promoting satiety. By imitating these actions, incretin mimetics help to regulate blood sugar levels in individuals with diabetes and glucose intolerance. One of the key benefits of incretin mimetics is its ability to lower blood sugar levels without causing hypoglycemia. This is especially important for individuals with diabetes who may experience dangerous drops in blood sugar levels when using other medications. Additionally, incretin mimetics have been shown to promote weight loss in some individuals, making them a valuable option for those struggling with obesity in addition to diabetes. Incretin mimetics are administered by injection, once or twice daily, depending on the specific medication. They are often combined with other diabetes medications, such as metformin or insulin, for optimal blood sugar control. These medications are generally well-tolerated, with common side effects including nausea, vomiting, and diarrhea, which usually diminish over time as the body adjusts to the medication. Studies have shown that incretin mimetics can help improve cardiovascular outcomes in individuals with diabetes, including reducing the risk of heart attacks and strokes. This is particularly significant given the increased risk of cardiovascular disease in individuals with diabetes. Incretin mimetics also have been shown to preserve pancreatic beta-cell function, which is responsible for producing insulin. This can help slow the progression of diabetes and reduce the need for higher insulin doses over time. Despite their many benefits, incretin mimetics are not without limitations. They can be expensive compared to other diabetes medications, which may make them less accessible for some individuals. Additionally, there have been concerns about the potential risk of pancreatitis and pancreatic cancer associated with the use of these medications. However, more research is needed to fully understand these risks. It is important for healthcare providers to carefully assess each individual's unique needs and medical history when considering the use of incretin mimetics. They may not be appropriate for everyone, particularly those with a history of pancreatitis or pancreatic cancer. Patients should also be educated about these medications' proper administration and potential side effects to ensure their safety and efficacy. Overall, incretin mimetics have emerged as an important therapeutic option for individuals with type 2 diabetes, offering a unique mechanism of action that can help improve blood sugar control, promote weight loss, and reduce cardiovascular risk. With ongoing research and development in this field, incretin mimetics continue to show promise as valuable tools in managing diabetes and its associated complications and comorbidities.


  • Open Access

    Can biophotonic therapy ameliorate the metabolic sequelae of NIDDM?

    by MD Orien L Tulp PhD, PhD George P Einstein

    Since antiquity, humans have sought the healing powers of sunshine to resolve many illnesses and restore a sensation of health and wellness. In recent publications, it has been reported that biophotonic treatment resulted in improvements in hemoglobin A1c and SpO2 concentrations in human subjects. In an animal study in which biophotonic treatment was applied to skeletal muscle in two models of Type 2 diabetes (NIDDM/T2DM), biophotonic treatment resulted in normalization of fasting and response plasma glucose concentrations and in an improvement in glycogen synthesis in skeletal muscle, likely secondary at least in part to improved GLUT4 actions and insulin sensitivity resulting in improved peripheral glucose uptake and oxidation and by increases in ATP generation in skeletal muscle. Because the biochemical mechanisms of carbohydrate metabolism and their contributions to the development of NIDDM are similar in both humans and in the animal models studied, the question arises as to whether biophotonic therapy might undergo consideration as an adjunct in the treatment of hyperglycemia, elevated HbA1c, peripheral oxygen delivery and wound healing in clinical management of NIDDM/T2DM. Biophotonic therapies have been widely used in the treatment of various infectious diseases and as an adjunct in anti-aging medicine, but the observations on parameters of intermediary metabolism in humans and animal models of NIDDM/T2DM reflect new findings believed to be of significant importance if applied to the clinical management of obesity, NIDDM and impaired glycemic states in humans.